Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

@article{GrilloLpez1999OverviewOT,
  title={Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.},
  author={Antonio J. Grillo-L{\'o}pez and Christine A. White and C L Varns and Dan-ping Shen and Andrew Zu-Sern Wei and Andrew McClure and Brian K. Dallaire},
  journal={Seminars in oncology},
  year={1999},
  volume={26 5 Suppl 14},
  pages={66-73}
}
Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) is a genetically engineered monoclonal antibody for the treatment of non-Hodgkin's lymphoma. This chimeric mouse/human, immunoglobulin GI kappa anti-CD20 antibody mediates complement-dependent cell lysis and antibody-dependent cellular cytotoxicity. It also has been shown to sensitize chemoresistant human lymphoma cell lines and to induce apoptosis. It was approved by the Food and Drug Administration… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 86 extracted citations

The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences • 2016
View 1 Excerpt

Cancer targeted therapeutics: From molecules to drug delivery vehicles.

Journal of controlled release : official journal of the Controlled Release Society • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…